COMPARISON OF THE INCIDENCE OF LATENT PROSTATE CANCER DETECTED AT AUTOPSY BEFORE AND AFTER THE PROSTATE SPECIFIC ANTIGEN ERA

Introdução: O câncer de próstata é a segunda neoplasia mais prevalente no sexo masculino no Brasil. Para homens com histórico familiar de câncer de próstata a prevenção é recomendada a partir de 45 anos e para os demais, a partir dos 65 anos para os demais. O objetivo deste estudo foi avaliar os níveis séricos de antígeno prostático específico (PSA) em pacientes diagnosticados com câncer de próstata antes e após o tratamento. Metodologia: Trata-se de um estudo descritivo, transversal e retrospectivo de abordagem quantitativa onde foram analisados pacientes diagnosticados com câncer de próstata no município de Parnaíba, Piauí, Brasil. Resultados: Foram incluídos 29 pacientes, com média de idade de 76,6 anos. De acordo com os resultados da dosagem do PSA antes (PSA1) e após (PSA2) o tratamento, 19 (65,5%) pacientes demonstraram queda nos valores de PSA2. O tratamento cirúrgico foi necessário em nove (31%) pacientes. A radioterapia foi realizada em 23 (79,3%) pacientes e seis (20,7%) estavam realizando tratamento com hormonioterapia. Nenhum paciente foi submetido a quimioterapia. Conclusão: Os resultados do presente estudo demonstraram quedas nos valores de PSA após o tratamento para câncer de próstata. Entretanto, é necessário propagar o conhecimento e conscientizar a população masculina sobre a importância da detecção precoce para que se tenha sucesso no prognóstico e aumente a procura dos homens pelos serviços de saúde e prevenção.

Download Full-text

Optimal Monitoring of Prostate-Specific Antigen Detects Prostate Cancer at the Localized Stage after Photoselective Vaporization for Benign Prostatic Hyperplasia

Current Urology ◽

10.1159/000489433 ◽

2018 ◽

Vol 12 (3) ◽

pp. 147-152

Author(s):

Jun Furusawa ◽

Yasushi Yamada ◽

Norihito Soga ◽

Isao Kuromatsu

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Clinical Stage ◽

Specific Antigen ◽

Optimal Monitoring ◽

Prostate Biopsies ◽

Before And After ◽

Photoselective Vaporization ◽

Diagnose Prostate Cancer ◽

Pathologic Analysis

Introduction: Photoselective vaporization of the prostate (PVP) does not provide prostate tissue for pathologic analysis. Here, we carried out early monitoring for prostate cancer by measuring prostate-specific antigen (PSA) levels and assessing clinicopathological features after PVP. Materials and Methods: Patients (n = 800) who underwent PVP and were followed-up for more than 12 months were analyzed retrospectively. After PVP, PSA levels were measured at 3 and 12 months and each year thereafter. Prostate biopsies were performed when PSA levels increased continuously. We assessed the characteristics of patients diagnosed with prostate cancer. Results: The mean follow-up period was 49 months. After PVP, 54 patients underwent biopsies, and 23 patients were diagnosed with prostate cancer. Overall, 10, 10, and 3 patients had clinical stage T1c, T2a, and T2b disease, respectively, and there were no cases of stage T2c disease or greater. Conclusions: We found that it was possible to diagnose prostate cancer at a localized stage under our optimal PSA monitoring schedule before and after PVP.

Download Full-text

An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

Cancer Urology ◽

10.17650/1726-9776-2020-16-3-90-101 ◽

2020 ◽

Vol 16 (3) ◽

pp. 90-101

Author(s):

B. Ya. Alekseev ◽

K. M. Nyushko ◽

R. A. Gafanov ◽

A. A. Kirichek ◽

Yu. V. Anzhiganova ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Castration Resistant Prostate Cancer ◽

Interventional Study ◽

Castration Resistant ◽

Before And After ◽

History Of ◽

The Russian Federation ◽

New Generation

Objective: to study the clinical and demographic profile of patients with non-metatstatic castration-resistant prostate cancer (nmCRPC) and clinical approaches to the treatment of nmCRPC in the context of daily medical practice before and after progression M1 stage.Materials and methods. The multicenter non-interventional epidemiological study is planned to include 200 patients with a documented diagnosis of nmCRPC from 2019 to 2020. The interim report has included data on 108 patients from 13 centers located in different regions of the Russian Federation. The median age of the patients was 73 (55—90) years.Results and conclusion. When the diagnosis of nmCRPC was made, the median prostate specific antigen was 8.23 (0.17—116.9) ng/ml, and the prostate specific antigen doubling time was 6 (1—50) months. When diagnosed nmCRPC, 86 patients (79.6 %) underwent a change of therapy, of which 42 % were prescribed modern regimens containing the new generation non-steroid antiandrogens (apalutamide, enzalutamide).

Download Full-text